Browse by Poster Presenter

Conference Program

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

A
Abdelmageed, Mai

Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida & Clinical Pharmacology and Pharmacometrics Department, Biogen MA Inc., USA
(T-001) A Model-based Pharmacokinetic Simulation Tool to Aid Dose Selection of Antisense Oligonucleotides Administered Intrathecally in Pediatrics
Mai Abdelmageed
Favorite
Abrams, Ruth

Daiichi Sankyo
(T-002) Representation of antibodies is key to generate a predictive vaccine quantitative systems pharmacology (QSP) model
Ruth Abrams
Favorite
Adam, Brian

Certara, Inc.
(M-001) Direct and Indirect Exposure-Response Modeling for Transthyretin Amyloid Cardiomyopathy Treated with Acoramidis
Brian Adam
Favorite
Adams, Dana

Genentech, Inc.
(W-035) Systems model to predict fractional exhaled nitric oxide response to inhaled JAK inhibitors in patients with mild to moderate asthma
Dana Adams
Favorite
Afzal, Nasrin

Genmab
(W-001) Leveraging quantitative systems pharmacology (QSP) modeling to understand effects of corticosteroids on immune cells and cytokine release following administration of SC Epcoritamab
Nasrin Afzal
Favorite
Ahadieh, Sima

Pfizer
(M-002) A Longitudinal Model-based Meta-Analysis (MBMA) of Body Weight in Obesity Trials
Sima Ahadieh
Favorite
Ahmed, Sameed

Takeda Pharmaceuticals
(T-005) A novel PBPK/PD model of preclinical data projects the human pharmacologically active dose of a Biologic that modulates immunosuppressive immune cells in the tumor microenvironment
Sameed Ahmed
Favorite
Al Hroot, Jomana

University of Iowa
(M-003) Determining an Appropriate Fosfomycin Dosing Regimen in Pneumonia Patients by Utilizing minimal PBPK Modeling and Target Attainment Analysis
Jomana Al Hroot
Favorite
Al Sahlawi, Sulafa

University of Florida
(T-006) Inhibitory Potential of Cannabidiol on Major CYP450s Enzymes: Insights from Physiological-based Pharmacokinetic Modeling
Sulafa Al Sahlawi
Favorite
Alexander, Gregory

Janssen Research & Development, La Jolla, California, USA.
(M-004) MBMA Bridging Models as A Tool for Exploration of Clinical Endpoints in Unstudied Indications.
Gregory Alexander
Favorite
Anderson, Wes

Critical Path Institute
(W-003) Leveraging Machine Learning and Real-World Data: Time-to-Event Analysis of COVID-19 Patients Using Electronic Health Records
Wes Anderson
Favorite
An, Yegwon

The State University of New York at Buffalo, School of Pharmacy & Pharmaceutical Sciences
(W-002) Dual Physiologically-based Pharmacokinetics Models of Nano-Liposomal (Nal-IRI) and Non-Liposomal Irinotecan in Ewing’s Family Tumor Xenograft
Yegwon An
Favorite
Arsène, Simon

Novadiscovery
(M-005) Coupling A Quantitative Systems Pharmacology Model With A Simple Statistical Layer To Predict Asthma Exacerbation Rate Reduction From Allergen Challenge Results
Simon Arsène
Favorite
(M-006) An innovative paradigm for non-small cell lung cancer clinical trial simulations through the Integration of a quantitative systemic pharmacology model and pharmacodynamic model of gemcitabine
Simon Arsène
Favorite
(M-007) Leveraging AI for improved reproducibility of mathematical disease models: insights from a retinitis pigmentosa case study
Simon Arsène
Favorite
(M-008) A within-host dynamic model of Bordetella pertussis to support vaccine development
Simon Arsène
Favorite
Arul Dhas, Blessed Winston

Christian Medical College, Vellore
(T-142) PK-PD modeling of doxycycline, azithromycin, and their combination in treating severe scrub typhus using a general pharmacodynamic interaction (GPDI) model.
Blessed Winston Arul Dhas
Favorite
Attah, Michael

Purdue/IUPUI
(T-007) Population Pharmacokinetics of Enoxaparin in Neonates and Infants
Michael Attah
Favorite
Avila Ponce De Leon, Marco
(T-017) Application of an advanced gut PBPK model to characterize intestinal transport and P-glycoprotein-mediated drug-drug interaction: a case study with Digoxin and Clarithromycin
Marco Avila Ponce De Leon
Favorite
Ayyar, Vivaswath

J&J Innovative Medicine
(T-008) Quantitative Systems Pharmacology (QSP) model for combined targeting of BAFF and CD40 pathways in systemic lupus erythematosus
Vivaswath Ayyar
Favorite
B
Babel, Heiko

AbbVie Inc.
(M-009) Combined multi-analyte population PK modeling of ABBV-400, a novel c-Met targeting ADC
Heiko Babel
Favorite
Bajaj, Gaurav

Genmab
(W-004) Development of QSP model of non-small cell lung cancer and its application to support optimal dose selection for acasunlimab, a bispecific antibody targeting 4-1BB and PD-L1
Gaurav Bajaj
Favorite
(W-005) Utilizing PBPK/RO model for description of GEN1042 (BNT312) PK and prediction of trimer level to guide dose selection
Gaurav Bajaj
Favorite
(W-006) Application of identifiability analysis to obtain reliable parameters of the QSP model describing mechanism of action GEN1042 (BNT312) and acasunlimab
Gaurav Bajaj
Favorite
Baron, Kyle

Metrum Research Group
(W-007) Simulating Adaptive Dosing Regimens from PK and PKPD Models Using mrgsolve
Kyle Baron
Favorite
Barua, Dipak

Translational Disease Modeling, Translational Medicine and Early Development, Sanofi R&D, Cambridge, US
(M-010) Quantitative system pharmacology model for tri-specific HER2xCD3xCD28 T-Cell Engager SAR443216
Dipak Barua
Favorite
Bedathuru, Dinesh

Vantage Research
(T-009) Development of QSP platform model for predicting clinical efficacy and CRS incidence of CD3 bispecifics in STEAP1 Prostate Cancer
Dinesh Bedathuru
Favorite
(T-010) A quantitative systems pharmacology model framework for combined clinical efficacy and hematological toxicity predictions for antibody drug conjugates
Dinesh Bedathuru
Favorite
Bender, Brendan

Genentech, Inc.
(T-011) A multi-stage modeling approach towards predicting cytokine release syndrome (CRS) in patients receiving Mosunetuzumab
Brendan Bender
Favorite
Bergstrand, Martin

Pharmetheus AB
(W-008) The reference corrected VPC (rcVPC) - An informative model diagnostic for assessing underlying exposure-response relationships
Martin Bergstrand
Favorite
Bewernitz, Michael

US Food and Drug Administration
(M-011) A Survey of Model Informed Approaches in Neuroscience Drug Development
Michael Bewernitz
Favorite
Bhagwat, Sharvari

Inhibrx Inc
(M-035) PK/PD Characterization of INBRX-140, a Novel anti-FcRn x anti-albumin bispecific antibody
Sharvari Bhagwat
Favorite
Bhattacharya, Souvik

Astellas Pharma
(M-012) Considerations for Industry—Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program
Souvik Bhattacharya
Favorite
Bishop, Corey

Clinical Pharmacology and Pharmacometrics Johnson & Johnson
(T-012) popPK & ER analysis of amivantamab in combination with chemotherapy for the treatment of patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer after osimertinib failure
Corey Bishop
Favorite
Boivin-Champeaux, Clémence

University of Florida
(M-013) Development of a quantitative systems pharmacology model for Hepatitis B Virus infection and Hepatitis D virus co-infection.
Clémence Boivin-Champeaux
Favorite
Bose, Maitreyee

Amgen
(T-013) A hybrid semi-mechanistic and machine learning framework to predict Cytokine Release Syndrome following T-cell engaging immunotherapies
Maitreyee Bose
Favorite
Bottino, Dean

Takeda Development Center America
(W-010) Modeling the evolution of activation marker distributions in flow cytometry data representing cell populations in patients dosed with immunomodulating agents
Dean Bottino
Favorite
Bozenhardt, Emily

J&J Innovative Medicine
(T-014) Longitudinal Population Pharmacokinetic/Pharmacodynamic Modeling of Continuous Efficacy Endpoint and Biomarker for a Novel Compound
Emily Bozenhardt
Favorite
Braniff, Nathaniel

Pfizer
(T-015) A quantitative systems pharmacology model to explore resistance mechanisms and combination strategies in ALK+ NSCLC targeted therapies
Nathaniel Braniff
Favorite
Brizzi, Francesco

Predictive Modelling and Data Analytics, Roche Pharma Research & Early Development, Roche Innovation Center Basel, Switzerland
(T-016) Bridging the Gap: A Comprehensive Checklist for Hybrid Pharmacometrics-Machine Learning Model Building to Support Oncology Clinical Development
Francesco Brizzi
Favorite
Budak, Maral

University of Michigan
(M-014) A systematic efficacy analysis of multidrug therapies for tuberculosis using a multi-scale agent-based model
Maral Budak
Favorite
Buyukozturk, Fulden

MathWorks
(T-017) Application of an advanced gut PBPK model to characterize intestinal transport and P-glycoprotein-mediated drug-drug interaction: a case study with Digoxin and Clarithromycin
Fulden Buyukozturk
Favorite
Byrne, Rena

Metrum Research Group
(W-011) Data Gaps, Model Mishaps: Quantifying the Impact of Missing Pharmacometrics Data on Pharmacodynamic Projections
Rena Byrne
Favorite
C
Cai, Lianjin

University of Pittsburgh
(M-015) Intranasal Diamorphine Population Pharmacokinetics Modeling and Simulation in Pediatric Breakthrough Pain
Lianjin Cai
Favorite
Callisto, Samuel

Metrum Research Group
(W-012) Reinforcement Learning for Pharmacometrics: A Proof of Concept and Future Directions
Samuel Callisto
Favorite
Cao, Youfang

Eisai, Inc
(T-018) A Neuro-Dynamic Quantitative Systems Pharmacology (QSP) Model to Describe Pathophysiology of Alzheimer’s Disease and Inform Drug Development
Youfang Cao
Favorite
Cassani, Simone
(T-019) Simulate modified Nonmem models using NMsim
Simone Cassani
Favorite
Cave, Joseph

Weill Cornell Medical College, Houston Methodist Research Institute
(M-016) Integrating Physiologically Based Pharmacokinetic Modeling with Machine Learning for the Rational Design of Nanoparticles to Improve Safety in Biomedical Applications
Joseph Cave
Favorite
Cha, Hwa Jun

Department of Pharmacology, College of Medicine, the Catholic University of Korea
(T-020) Zolpidemsim: A Web-Application for Simulating Pharmacokinetics of Zolpidem
Hwa Jun Cha
Favorite
Chamzas, Athanasios

University of Maryland School of Pharmacy, Center for Translational Medicine, Baltimore, MD
(W-013) Patent Ductus Arteriosus in Preterm Infants: Exploring Optimal Acetaminophen Dosing for Oral and Rectal Administration
Athanasios Chamzas
Favorite
Chan, Danna

Taiho Oncology, Inc.
(T-021) Semi-physiological population pharmacokinetic (PPK) model using dose optimization data for ASTX030, an oral fixed-dose combination (FDC) of CDA inhibitor cedazuridine and azacitidine in MDS patients
Danna Chan
Favorite
Chang, Yi Chien

University at Buffalo
(T-022) Comparing the Efficacy of Various Insulin Types: A Pharmacokinetic and Pharmacodynamic Modeling Study in Healthy Volunteers
Yi Chien Chang
Favorite
Cheng, ChunFu

University at Buffalo
(T-025) Meta-Analysis of Levamisole Pharmacokinetics Across Diverse Species
ChunFu Cheng
Favorite
Chen, Jingcheng

Drug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China
(T-060) AI-Driven Innovative Platform in Quantitative Pharmacology: Literature Insights and Automated Model Construction
Jingcheng Chen
Favorite
Chen, Joseph

Genentech
(W-014) Model-Based Meta Analysis for the IPSOS Trial in Platinum Ineligible NSCLC Patients
Joseph Chen
Favorite
Chen, Li

Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill
(M-017) A Semi-mechanistic Pharmacokinetic-Pharmacodynamic/Toxicodynamic Model to Guide Dose Optimization of Combination Therapies Targeting DNA Damage Response Pathways
Li Chen
Favorite
Chen, Min

Fudan University
(T-023) Cost-effectiveness of paliperidone palmitate long-acting injectables for the treatment of schizophrenic patients: a joint pharmacometric/pharmacoeconomic approach
Min Chen
Favorite
Chen, Po-Wei

Amgen Inc.
(T-024) A Bayesian Approach to Item Response Theory Modeling for Exposure-Response Relationships in Stan
Po-Wei Chen
Favorite
Chittenden, Jason
(T-026) A Semi-Mechanistic Population Pharmacokinetic (PopPK) Model of Linvoseltamab With Considerations of Disease-Related Factors in Patients (Pts) with Relapsed/refractory (RR) Multiple Myeloma (MM)
Jason Chittenden
Favorite
Choi, Suein

Catholic university of Korea
(T-027) Integrated Microphysiological System and PBPK Modeling for Prediction of Human Diclofenac Pharmacokinetics
Suein Choi
Favorite
Cho, Yu Kyoung

Johnson and Johnson Innovative Medicine
(M-018) Population Pharmacokinetic Assessment of Guselkumab in Adults with Moderately to Severely Active Ulcerative Colitis
Yu Kyoung Cho
Favorite
Clemens, Lara

Simulations Plus, Inc.
(W-015) Eculizumab as a Key Comparator for the Evaluation of Complement Targeted Novel Therapeutic Strategies with a QSP Model
Lara Clemens
Favorite
Cobbina, Enoch

Syndax Pharmceuticals, Inc., Walthman, MA
(W-016) Revumenib physiologically based pharmacokinetic model for evaluation of age effect and CYP3A4-mediated drug-drug interaction in relapsed/refractory acute leukemias
Enoch Cobbina
Favorite
Collins, Kimberly

Critical Path Institute
(M-019) Predictors Of Insulin Dose In Individuals With New-Onset Type 1 Diabetes
Kimberly Collins
Favorite
Combes, francois

Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
(T-028) Pooled population PK of alpelisib in patients with PIK3CA-related overgrowth spectrum and breast cancer
francois Combes
Favorite
Cortes-Rios, Javiera

University at Buffalo
(W-017) Integrating mathematical modeling with multiplexed immunofluorescence data to predict drug-induced cell arrest
Javiera Cortes-Rios
Favorite
(W-018) Novel computational workflow for selecting virtual patient cohorts for in silico clinical trials
Javiera Cortes-Rios
Favorite
Couty, Claire

Nova In Silico
(M-020) Dissecting Bcl-2 Sensitivity In Acute Myeloid Leukemia: A Quantitative Systems Pharmacology Model For Venetoclax-Azacitidine Therapy
Claire Couty
Favorite
(M-021) Towards A Computational QSP Platform To Support Antibody Drug Conjugate Design In Cancer
Claire Couty
Favorite
(M-022) Towards A QSP Platform To Support Drug Development In Hematological Cancers
Claire Couty
Favorite
Cui, Cheng
(W-129) Frailty phenotype as a sensitive indicator of aging-related Cytochrome P450 3A functional changes：Application of dose optimization recommendations for ticagrelor in the Chinese frail older population
Cheng Cui
Favorite
Cui, Zihan

Critical Path Institute
(T-029) An R-based workflow for clinical trial simulation tool with application in type 1 diabetes studies
Zihan Cui
Favorite
D
Dalton, Mackenzie

Clarkson University
(M-023) Evaluating the Importance of Glucagon in the Insulin-Glucose Regulatory System: A Mechanistic Modeling Approach
Mackenzie Dalton
Favorite
Davenport, Angelica

Genmab
(T-030) Integration of Temporal Single-Cell RNA Sequencing Data into Quantitative Systems Pharmacology Model of T Cell Differentiation
Angelica Davenport
Favorite
D'Cunha, Ronilda

AbbVie
(M-075) Leveraging Digital Biomarkers to Enhance Clinical Pharmacology and Pharmacometrics Informed Drug Development: A Case Study
Ronilda D'Cunha
Favorite
de Jong, Jan

Immuneering Corporation
(W-019) Phase 1 Interim Population Pharmacokinetic/Pharmacodynamic Model and Phase 2 Dose Exploration for IMM-1-104, a Novel Concept Oral Deep Cyclic MEK Inhibitor.
Jan de Jong
Favorite
De Witte, Wilhelmus

ESQlabs
(W-020) In-depth numerical model analysis tools to gain insight into model behavior of large-scale pharmacometric models
Wilhelmus De Witte
Favorite
(W-021) Local TMDD of large molecules in tissue interstitial space
Wilhelmus De Witte
Favorite
Debroy, Swati

Certara
(W-022) Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease
Swati Debroy
Favorite
Dela, An

Simulations Plus
(T-031) Comparison of Sensitivity Analysis Methods in the Context of a QSP Model for Gout
An Dela
Favorite
Delff, Philip

Vertex Pharmaceuticals
(T-032) NMsim: Simulate Nonmem models seamlessly in R without any model reimplementation
Philip Delff
Favorite
Demin Jr, Oleg

InSysBio CY
(M-024) Mechanistic Translational Modeling Versus Minimal Anticipated Biological Effect Level Approach to Predict First-in-human Dose For T-cell Engagers: HPN536 Case Study.
Oleg Demin Jr
Favorite
(T-047) FIVEDB as a tool for analysis of in vitro experimental data: cytokine production by primary cells and cell lines
Oleg Demin Jr
Favorite
(W-060) Quantitative systems pharmacology model for distinguishing efficacy of anti-CD20 therapy variants in populations of Multiple Sclerosis patients
Oleg Demin Jr
Favorite
(W-061) Quantitative systems pharmacology modeling of neurotoxicity and cognitive scores in Alzheimer’s disease for prediction of therapy outcomes
Oleg Demin Jr
Favorite
Denney, William S

Human Predictions
(W-023) Optimized Noncompartmental Half-Life Estimation with Tobit Regression
William S Denney
Favorite
Desai, Devam

Center of Pharmacometrics and Systems Pharmacology, University of Florida, Orlando, FL
(T-033) A translational one pore and two pore whole body physiologically based pharmacokinetic model for ASOs, and siRNA-based therapeutics
Devam Desai
Favorite
Dhakal, Saroj

Sanofi
(W-024) Small molecule exposure prediction (intravenous (IV) and oral (PO)) using Machine learning (ML) in combination with mechanistic modeling.
Saroj Dhakal
Favorite
DiBartolo, Sarah
(M-025) A quantitative systems pharmacology (QSP) model to enable prediction of ARIA-E incidence with anti-Aβ monoclonal antibody therapies for Alzheimer’s disease
Sarah DiBartolo
Favorite
Djebli, Nassim

Luzsana Biotechnology
(W-049) Exposure-Response Analysis for Hepatotoxicity of Rivoceranib Monotherapy and in Combination with Camrelizumab in Patients with Various Cancers, Including Advanced Hepatocellular Carcinoma
Nassim Djebli
Favorite
Dodds, Michael

Certara USA, Inc
(M-026) Augmented Definitive Screening Design Provides Efficient Phase 1 Selection of CAR T-cell and Lymphodepletion Regimen
Michael Dodds
Favorite
Dogra, Prashant

Houston Methodist Research Institute
(T-034) Translational modeling identifies synergistic combinations of anti-microRNA-155 with standard-of-care drugs in non-small-cell lung cancer
Prashant Dogra
Favorite
(T-035) Identifying Determinants of Vaccine Efficacy: A Mechanistic Modeling Approach
Prashant Dogra
Favorite
Doi, Yohei

Faculty of Pharmaceutical Sciences, Kyushu Univercity, Fukuoka, Japan
(M-027) Model-based meta-analysis of safety for monomethyl auristatin E-conjugated antibody drug conjugates in cancer patients
Yohei Doi
Favorite
Dombrowsky, Erin

Bristol Myers Squibb
(M-028) A systematic approach for imputing missing dose information in population pharmacokinetic analysis datasets
Erin Dombrowsky
Favorite
Dong, Jin

AstraZeneca
(M-029) Bilirubin Elevation Due To Atazanavir Treatment May Primarily Be Mediated By Inhibition Of OATP1B1/3 Rather Than That Of UGT1A1: PBPK Analysis Of Bilirubin-Atazanavir-Polymorphism Interaction
Jin Dong
Favorite
Dotan, Or

Teva Pharmaceuticals, Ltd.
(W-025) Population pharmacokinetic analysis of anti-interleukin-15 monoclonal antibody TEV-53408 in healthy volunteers
Or Dotan
Favorite
(W-026) Population pharmacokinetic and pharmacodynamic analysis of natural killer cell levels in response to TEV-53408, an anti-interleukin 15 monoclonal antibody, in healthy volunteers
Or Dotan
Favorite
Drescher, Stefanie

Pfizer INC
(W-027) Population Pharmacokinetic (PopPK) Model to Characterize Pharmacokinetics (PK) of Vepdegestrant, a Proteolysis Targeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Healthy Adult Participants
Stefanie Drescher
Favorite
Duffull, Stephen

Certara
(M-031) Development and application of a mechanistic model for Alzheimer’s Disease
Stephen Duffull
Favorite
Du, Lihong

Merck & Co., Inc.,
(M-030) A Minimal QSP Model for Treg Responses of IL-2 Mutein MK-6194 – A Conceptual Model for Autoimmune Disease
Lihong Du
Favorite
Duong, Khanh Linh

Chungnam National Univesity
(W-028) Development and application of physiologically based pharmacokinetic model of darunavir on pregnant population
Khanh Linh Duong
Favorite
Du, Ruihu

Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China
(T-038) The PK-PD model of dexamethasone for fetal lung maturation and developmental neurotoxicity: A dose optimization study
Ruihu Du
Favorite
du, Shengnan

BMS
(T-036) A Novel Empirical Drug Induced Autoinduction Model to Characterize the Population Pharmacokinetics of Repotrectinib with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Shengnan du
Favorite
(T-037) Exposure-Response Efficacy and Safety Analysis of Repotrectinib to Support the Dose Recommendation for Patients with ROS1-positive NSCLC
Shengnan du
Favorite
E
Elmokadem, Ahmed

Metrum Research Group
(T-039) Symbolic PBPK-PDE Modeling Using Open-Source Julia Tools
Ahmed Elmokadem
Favorite
(T-040) How to Make a Salad? Rethinking Pharmacometric/QSP Model Composition Using Open-Source Julia Tools
Ahmed Elmokadem
Favorite
Eriksson, Johanna

Pharmetheus
(W-029) Physiologically based pharmacokinetic modelling to support the development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis: An MIDD case study
Johanna Eriksson
Favorite
F
Fang, Yunlan

Clinical Pharmacology and Pharmacometrics, Incyte
(W-030) Population Pharmacokinetics/Pharmacodynamics Modeling of INCAGN02390 in Patients with Select Advanced Malignancies
Yunlan Fang
Favorite
Fan, Xiaoqing

The Chinese University of Hong Kong
(M-032) A Whole-body Mechanistic Physiologically-based Pharmacokinetic Modeling of Intravenous Iron
Xiaoqing Fan
Favorite
Fidler, Matthew

Novartis
(M-033) babelmixr2 and PopED: Quick Conversion of NONMEM, Monolix and nlmixr2/rxode2 Models to PopED Optimal Design Analysis
Matthew Fidler
Favorite
Fisher, Jeannine

Metrum Research Group
(W-031) Scientific Project Management (SPM) to Enhance Model-Informed Drug Development
Jeannine Fisher
Favorite
Fostvedt, Luke

Pfizer, Inc.
(W-032) Longitudinal Joint Modeling of Modified Mayo Score and Dropout in Patients with Moderate to Severely Active Ulcerative Colitis.
Luke Fostvedt
Favorite
Friedrich, Christina

Rosa & Co
(W-033) Adaptation of a Published Kidney Disease QSP Model to Represent Autosomal-Dominant Polycystic Kidney Disease and Evaluate Treatment Options
Christina Friedrich
Favorite
(W-034) Parallel Tempering for Generation of Virtual Patients and Virtual Populations
Christina Friedrich
Favorite
G
Gadkar, Kapil

Genentech
(W-035) Systems model to predict fractional exhaled nitric oxide response to inhaled JAK inhibitors in patients with mild to moderate asthma
Kapil Gadkar
Favorite
Gaffney, Anna

Certara USA, Inc., Radnor, PA
(M-034) Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models
Anna Gaffney
Favorite
Gallais, Fanny

Pharmetheus AB
(T-041) Bimekizumab population pharmacokinetic and exposure-response analyses in adults with moderate to severe hidradenitis suppurativa
Fanny Gallais
Favorite
Gao, Xizhe

Pfizer Inc
(W-070) Concentration-QTc Analysis of PF-07220060 in Patients with Advanced Solid Tumors
Xizhe Gao
Favorite
Gastonguay, Marc

Metrum Research Group
(M-036) Pharmacometric-Pharmacoeconomic Modeling and Simulation in Atopic Dermatitis: Informing Early Drug Development Decisions for a Hypothetical New Therapeutic
Marc Gastonguay
Favorite
Gaudreault, Francois

Vigil Neuroscience, Inc
(T-042) Use of Model-informed Drug Development and Natural History Data to Inform the Development of Iluzanebart in ALSP: A Neurological Rare Disease
Francois Gaudreault
Favorite
Gebhart, Anthony

University of Florida - Center for Pharmacometrics & Systems Pharmacology
(T-043) Advancing Drug Development through Enhanced Exposure-Response Analysis: The R-Shiny App ERpmx
Anthony Gebhart
Favorite
Gharahi, Hamidreza

Takeda Pharmaceuticals
(T-044) A translational quantitative systems pharmacology modeling framework for FcRn antagonist therapy for myasthenia gravis
Hamidreza Gharahi
Favorite
Ghasemi, Mohammad

Arcus Biosciences
(W-036) Population Plasma and Urine Pharmacokinetic Data and Modelling of Casdatifan Supports Administration to Participants with Moderate Renal Impairment
Mohammad Ghasemi
Favorite
Gonzalez, Juan

Pumas-AI, Inc.
(W-037) Evaluation of Large Language Models for an AI Chat Assistant Focused on Pumas and Pharmacometrics
Juan Gonzalez
Favorite
Goo, Sungwoo

Chungnam National University
(T-045) Mixed effect state space model application for data driven pharmacometrics modeling
Sungwoo Goo
Favorite
Gordi, Toufigh

Rigel Pharmaceuticals
(T-046) A Mixed-effect Pharmacokinetic Model of R835, a Novel Dual IRAK1/4, in Healthy Volunteers After Administration of the Prodrug R289
Toufigh Gordi
Favorite
Goryacheva, Ekaterina

InSysBio UK
(T-047) FIVEDB as a tool for analysis of in vitro experimental data: cytokine production by primary cells and cell lines
Ekaterina Goryacheva
Favorite
Gosselin, Nathalie

Certara
(M-037) K-PD model of Plozasiran in Patients with Severe Hypertriglyceridemia
Nathalie Gosselin
Favorite
(M-038) K-PD Modeling of Plozasiran - Mixed Hyperlipidemia
Nathalie Gosselin
Favorite
Greenwald, Eric

Pfizer Inc
(T-048) App-based in vitro pharmacokinetic driver identification and in silico clinical trial assessment of pharmacokinetic driver models
Eric Greenwald
Favorite
Grinshpun, Boris

Certara USA, Radnor, PA
(T-049) Building Automated Pharmacometrics Analysis Workflows in R with NMsim
Boris Grinshpun
Favorite
Guimaraes, Mariana

ESQlabs GmbH
(T-050) A review of OSP suite PBBM capabilities: looking ahead
Mariana Guimaraes
Favorite
Guo, Yang

Alexion Pharmaceuticals, Inc.
(T-099) Acoramidis (ALXN2060) Population Pharmacokinetic Modeling and the Importance of Exploring Categorization of Covariate Values
Yang Guo
Favorite
Gupta, Kajal

University of Florida
(M-039) A PBPK-QSP model for regulation of thyroid hormones in Allan-Herndon Dudley Syndrome
Kajal Gupta
Favorite
H
Hai, Min

The Ohio State University
(T-053) Modeling and inter-species scaling of plasma DHO as a biomarker to inform first-in-human dose selection for a novel DHODH inhibitor
Min Hai
Favorite
Hajjawi, Malek

Indiana University School of Medicine
(W-038) Development of a Physiologically-Based Pharmacokinetic (PBPK) Model for Caffeine in Pregnancy: Evaluating Neonatal Transfer
Malek Hajjawi
Favorite
(W-039) Predictive Pharmacokinetic Analysis of Novel PLCG2 Inhibitors Using GastroPlus and ADMET Predictor
Malek Hajjawi
Favorite
Hamada, Izumi

Bristol Myers Squibb
(M-040) Novel endpoints based on tumor growth dynamics – A comprehensive simulation study with retrospective validation
Izumi Hamada
Favorite
Hasegawa, Chihiro

Merck Sharp & Dohme
(M-041) Exploring Best Practices of the Population Pharmacokinetic Modeling for Antibody-Drug Conjugates – a Simulation Study
Chihiro Hasegawa
Favorite
(M-042) Model-Informed Dose Justifications and Clinical Pharmacology Strategy of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal Infection
Chihiro Hasegawa
Favorite
Heathman, Michael

Metrum Research Group
(T-054) The effect of CYP2B6 genotype on the clearance and autoinduction of efavirenz in healthy subjects and the subsequent impact on efavirenz exposure.
Michael Heathman
Favorite
Hennion, Maud

Cencora Pharmalex
(T-055) Population PK model on preclinical data for optimization of further clinical trial designs in oncology
Maud Hennion
Favorite
Henscheid, Nick

Critical Path Institute
(W-040) Extracting Lab Value Reference Ranges from Neonatal Real-World Data in OMOP Format
Nick Henscheid
Favorite
Her, Lucy

Eli Lilly
(M-043) Image Processing with Spatial Modeling of Neural Tissue: A New Approach to Pharmacokinetic Analysis
Lucy Her
Favorite
Herrera Reyes, Alejandra Donaji

Merck & Co., Inc., Rahway, NJ, USA
(W-041) Inferring HIV rebound timing from a noisy biomarker
Alejandra Donaji Herrera Reyes
Favorite
Herron, Cody

Pfizer
(M-044) MIDD Platform of VZV Vaccine Immunogenicity and Efficacy
Cody Herron
Favorite
He, Yanna

IMPACT Therapeutics, Inc. (Shanghai)
(W-132) Population Pharmacokinetic Modeling of IMP7068 in Patients with Advanced Solid Tumors
Yanna He
Favorite
Hooker, Andrew

Uppsala University
(T-056) A modified Bayesian information criterion (mBIC) with multiple testing correction for population pharmacokinetic model building
Andrew Hooker
Favorite
Hosawi, Anhar

University of Cincinnati / Cincinnati Children's Hospital Medical Center
(W-042) Population Pharmacokinetic Modeling of Hydroxyurea in Plasma and Breast Milk in Lactating Women
Anhar Hosawi
Favorite
Huang, Hannah

Arcus Biosciences
(W-045) Clinical Trial Simulation to Assess Sample Size and Power For Detecting Differences in Pharmacokinetic Exposure Metrics
Hannah Huang
Favorite
Huang, Weize

Genentech
(M-046) Development and Application of Inavolisib Physiologically-based Pharmacokinetic (PBPK) Model for Drug-drug Interaction (DDI) Assessment
Weize Huang
Favorite
Huang, Yunda

Fred Hutchinson Cancer Center
(W-140) Pharmacokinetics Analysis of Serum and Rectal Tissue Concentrations of VRC01 and VRC01LS in People Without HIV in a Phase 1 Clinical Trial (HVTN 116)
Yunda Huang
Favorite
Hu, Chuanpu

Bristol Myers Squibb
(M-045) Visual predictive check of longitudinal models and dropout
Chuanpu Hu
Favorite
Hudson, Rachel

Bristol Myers Squibb
(M-047) Population Pharmacokinetics of Nivolumab in Patients with Newly Diagnosed or Relapsed/Refractory Classical Hodgkin Lymphoma
Rachel Hudson
Favorite
Hughes, Jasmine

InsightRX
(M-048) mipdtrial: an open-source R package for simulating model-informed precision dosing trials
Jasmine Hughes
Favorite
Hu, Hongxiang

BMS
(W-043) Early sBCMA Kinetics as a Potential Indicator of Progression-Free Survival in Relapsed/Refractory Multiple Myeloma Patients Receiving CAR T-Cell Therapy
Hongxiang Hu
Favorite
(W-044) Population Cellular Kinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Hongxiang Hu
Favorite
Hurtado, Felipe

Daiichi Sankyo, Inc.
(T-064) Pharmacokinetic-pharmacodynamic analysis of myelosuppression with raludotatug deruxtecan (R-DXd) in patients with advanced solid tumors
Felipe Hurtado
Favorite
Hynes, Scott

Biogen Inc.
(T-136) Unique Effect of the High-Fat Meal on the Pharmacokinetics of Omaveloxolone Explained by Physiologically Based Biopharmaceutics Modeling
Scott Hynes
Favorite
I
Inoue, Hiroyuki

Daiichi Sankyo
(W-046) Population Pharmacokinetic and Exposure-Response Modelling Analyses to Support Valemetostat Dose Recommendations in Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)
Hiroyuki Inoue
Favorite
Irie, Kei

Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center
(T-057) Hybrid Population PK-Machine Learning Model Approach to Predict Infliximab Concentrations in Pediatric Patients with Crohn's Disease
Kei Irie
Favorite
Ismail, Mohamed

Enhanced Pharmacodynamics LLC
(W-047) Mechanistic PK/PD modeling of the simultaneous effects of bepirovirsen on hepatitis B surface antigen (HBsAg) and ALT in participants with chronic hepatitis B infection to support Phase 3 study design
Mohamed Ismail
Favorite
Ivanova, Olga

Incyte Research Institute
(W-048) Itacitinib Population Pharmacokinetics (PopPK) and Exposure-Response for Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy: Results From Phase 2 Study NCT04071366
Olga Ivanova
Favorite
J
Jadhav, Satyawan

Alnylam Pharmaceuticals
(M-049) Disease Progression Modeling of Stargardt’s disease
Satyawan Jadhav
Favorite
Jarugula, Praneeth

Bristol Myers Squibb
(W-050) Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analysis of Danicamtiv in Heart Failure with Reduced Ejection Fraction
Praneeth Jarugula
Favorite
Javidi, Mehrdad
(M-004) MBMA Bridging Models as A Tool for Exploration of Clinical Endpoints in Unstudied Indications.
Mehrdad Javidi
Favorite
Jayachandran, Priya

Regeneron Pharmaceuticals, Inc.
(W-051) Model-based ‘learn and confirm approach’ demonstrates similarity of cemiplimab exposure in pediatric and adult populations
Priya Jayachandran
Favorite
Jeon, Jihyun

Chungnam National University
(T-058) Exposure-response (E-R) relationship between PD-L1 recombinant monoclonal antibody IMC-001 in relapsed or refractory extranodal NK/T cell lymphoma nasal type patients
Jihyun Jeon
Favorite
Jeon, Jiyeon

Chungnam National University
(T-059) Population Pharmacokinetic Approach to Evaluate Current Recommended Dose of Tacrolimus on Korean Pediatric Liver Transplant Patients
Jiyeon Jeon
Favorite
Jiang, Weihua

School of Pharmacy and Pharmaceutical Sciences, University at Buffalo
(W-052) Hybrid Minimal Physiological-Based Pharmacokinetic Model of Tenofovir Alafenamide and Its Metabolites Disposition in Humans
Weihua Jiang
Favorite
Job, Kathleen

The University of Utah
(W-054) Effects of sparse sampling in the characterization of leuprolide pharmacokinetics and pharmacodynamics in patients with prostate cancer
Kathleen Job
Favorite
Johnson, Carter

Certara
(T-061) Impact of PD-L2 on Relative Efficacy of Anti-PD-1 and Anti-PD-L1 Antibodies: Insights From QSP-Based Meta-Analysis
Carter Johnson
Favorite
Johnson, Jordon

Arcus Biosciences Inc.
(W-055) Confounding Impact of Event-Driven Exposure Phenomenon on Summary Exposure Metrics in Time-to-Event Exposure Response Analyses
Jordon Johnson
Favorite
(W-056) Population Pharmacokinetics of Quemliclustat, a Potent, Selective, and Reversible CD73 Inhibitor, in Patients with Cancer
Jordon Johnson
Favorite
Jomphe, Claudia

Certara
(M-037) K-PD model of Plozasiran in Patients with Severe Hypertriglyceridemia
Claudia Jomphe
Favorite
Jones, Hannah

Certara, Simcyp Consultancy Division
(W-124) Real world examples of PBPK impact on CYP3A4 victim DDI drug label content
Hannah Jones
Favorite
Jonsson, E. Niclas

Pharmetheus AB
(M-051) The impact of misspecified covariate models on inclusion and omission bias when using FREM and FFEM
E. Niclas Jonsson
Favorite
Jonsson, Fredrik

qPharmetra LLC
(M-050) Exposure-Response Analysis of Cenobamate
Fredrik Jonsson
Favorite
Jo, Seongjun

The State University of New York at Buffalo
(W-053) Development of physiologically based pharmacokinetic models for RET inhibitors to predict brain distribution
Seongjun Jo
Favorite
Joslyn, Louis

Preclinical and Translational Pharmacokinetics/Pharmacodynamics, Genentech
(T-062) A Pharmacologically-informed Neural Ordinary Differential Equation Framework to Predict Preclinical Pharmacokinetics
Louis Joslyn
Favorite
K
Kaddi, Chanchala

Sanofi
(W-058) QSP-based virtual twin approach provides mechanistic insight into enzyme replacement therapies in Pompe Disease
Chanchala Kaddi
Favorite
Kang, Jia

Metrum Research Group, USA
(M-052) Accounting For Dose Modifications In Exposure-Response Analyses In Oncology: The Case Example Of Brigimadlin
Jia Kang
Favorite
Kang, Jueun

catholic university
(M-053) PKPD modeling and simulation of an inhaled antibiotic targeting Gram-negative bacteria, using a bacteriophage-derived endolysin.
Jueun Kang
Favorite
Kapitanov, Georgi

Certara
(M-054) Preclinical data exposures underpredict clinical physiologically active doses for bispecific TCEs in solid tumors indications; are there better metrics? - insights from a small mechanistic MBMA
Georgi Kapitanov
Favorite
Karelina, Tatiana

InSysBio CY
(W-060) Quantitative systems pharmacology model for distinguishing efficacy of anti-CD20 therapy variants in populations of Multiple Sclerosis patients
Tatiana Karelina
Favorite
(W-061) Quantitative systems pharmacology modeling of neurotoxicity and cognitive scores in Alzheimer’s disease for prediction of therapy outcomes
Tatiana Karelina
Favorite
Kashihara, Yushi

Daiichi Sankyo Co., Ltd.
(M-055) Immune Correlates of Protection against Respiratory Syncytial Virus Infection and an Application to Model-Informed Vaccine Development for an internal compound: a Model-Based Meta-Analysis
Yushi Kashihara
Favorite
K, Ayan

The Critical Path Institute
(W-057) Optimizing Drug Development: Assessing Small Language Models for Efficient Drug-Drug Interaction Data Extraction
Ayan K
Favorite
Kenz, Zackary

Simulations Plus
(T-065) Weight Loss and Nausea from Subcutaneous and Oral Semaglutide Accurately Simulated with a QSP Model
Zackary Kenz
Favorite
Khaksar Toroghi, Masood

Takeda Development Center Americas Inc
(M-056) A Translational Quantitative Systems Pharmacology (QSP) Modeling Framework to Predict Interleukin-15 (IL-15) Cytokine Levels in Multiple Myeloma Patients after Anti-BCMA CAR-NK Cell Therapy
Masood Khaksar Toroghi
Favorite
Khoei, Adrian

UNC Eshelman School of Pharmacy
(T-066) A Novel Concentration-Based Time-Imputation Algorithm for Large Cohort Studies Missing Time-After-Dose Data for Stored Samples
Adrian Khoei
Favorite
Khusial, Richard

Certara
(M-057) A Pharmacokinetic Analysis of Drug Concentration Using a Novel Deep Learning Model
Richard Khusial
Favorite
Khwarg, Juyoung

Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital
(W-062) SEMI-PHYSIOLOGIC POPULATION PHARMACOKINETIC MODEL TO EVALUATE THE EFFECT OF HEPATIC-UPTAKE TRANSPORTER GENE SLC22A1 POLYMORPHISM ON PHARMACOKINETICS OF PROGUANIL AND ITS METABOLITE, CYCLOGUANIL
Juyoung Khwarg
Favorite
Kim, Chaejin

Takeda Development Center Americas Inc.
(W-065) Extrapolation of Efficacy and Simplification and Optimization of Pediatric Clinical Trial Design for Azilsartan Medoxomil (Edarbi) through Modeling and Simulation
Chaejin Kim
Favorite
Kim, Dong hyun

Department of Regulatory Science, College of Pharmacy, Graduate School, Kyung Hee University
(T-067) A quantitative systems pharmacology-physiologically based pharmacokinetic model-guided antibiotics regimen design for the treatment of sepsis and septic shock patients
Dong hyun Kim
Favorite
Kim, Hyeon Ji

Kyung Hee University, Seoul, Republic of Korea
(T-069) Assessment of Disease Similarity among Different Racial and/or Ethnic Groups in Oncology: ABC Framework
Hyeon Ji Kim
Favorite
kim, hyeonsu

Kyunghee university department of pharmacy
(W-064) Comparative evaluation of different vancomycin population pharmacokinetic models to predict Bayesian-estimated vancomycin AUC in Korean patients
hyeonsu kim
Favorite
Kim, Kyeongmin

The Ohio State University
(T-068) An integrated model of catabolic clearance mechanisms driving exposure-response confounding for immunotherapies in cancer: interactions between mAb drugs, Fc receptors, and endogenous serum proteins
Kyeongmin Kim
Favorite
Kim, Min-Soo

School of Pharmacy, University of Waterloo
(M-059) Physiologically based pharmacokinetic (PBPK) modeling of methotrexate in cerebrospinal fluid in humans
Min-Soo Kim
Favorite
Kim, Se Jin

Department of Pharmaceutical Sciences, University at Buffalo
(W-063) Cell-line Specific Network Modeling to Assess Differential Signal Transduction of Oxaliplatin-based Drug Combinations for Colorectal Cancer
Se Jin Kim
Favorite
Kim, Yoonjin

Seoul National University College of Medicine and Hospital
(M-058) Pharmacokinetic/Pharmacodynamic Modeling for Dose Selection of S-001, a Novel mRNA-based Therapy for Pancreatic Cancer
Yoonjin Kim
Favorite
Klee, Brandon

St. Jude Children's Research Hosptial
(M-060) Impact of Drug Interactions and Genetic Variability on High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia
Brandon Klee
Favorite
Kom Nzia, Jeanne Dulie

Nurix Therapeutics
(W-066) PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF PIOGLITAZONE: EVALUATING THE EFFECT OF THE CYTOCHROME P450 2C8*2 SINGLE NUCLEOTIDE POLYMORPHISM
Jeanne Dulie Kom Nzia
Favorite
kondic, anna

BMS
(T-070) A novel model for Platelets Dynamics: a pragmatic systems approach to characterize thrombocytopenia across multiple compounds and drug classes
anna kondic
Favorite
Korsbo, Niklas

DeepPumas, Pumas-AI Inc.
(T-071) A Framework for Evaluating Predictive Models Using Synthetic Image Covariates and Longitudinal Data
Niklas Korsbo
Favorite
Kosinski, Luke

Critical Path Institute
(M-061) A clinical trial simulator tool for a randomized delayed start trial in Parkinson’s disease
Luke Kosinski
Favorite
Krzyzanski, Wojciech

University at Buffalo
(W-067) Gauss-Hermite cohort population estimation of dexamethasone pharmacokinetic parameters in pregnant women using blood samples collected at birth
Wojciech Krzyzanski
Favorite
Kuchimanchi, Mita

GSK, Waltham, MA, USA
(T-072) Exposure–Response Relationship of Dostarlimab With Chemotherapy in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis Two of Part 1 of ENGOT-EN6-NSGO/GOG-3031/RUBY Trial
Mita Kuchimanchi
Favorite
Kulesza, Alexander

esqLABS
(T-073) Bispecific T-cell engagers and cytokine release syndrome: Modeling molecule, indication and patient-specific aspects
Alexander Kulesza
Favorite
Kumar, Ansu

Cellworks Research India Pvt Limited
(T-074) Risk Assessment for Drug-Induced Hyperbilirubinemia: A Mechanistic Approach
Ansu Kumar
Favorite
Kumar, Rajeev

CELLWORKS GROUP, INC.
(T-074) Risk Assessment for Drug-Induced Hyperbilirubinemia: A Mechanistic Approach
Rajeev Kumar
Favorite
L
Lachi Silva, Larissa

Novartis Pharmaceuticals Corporation
(W-068) Dose determination of Lutathera in adolescents via popPK and dosimetry modeling and simulation
Larissa Lachi Silva
Favorite
Laffont, Celine

Indivior Inc
(M-092) Integrated Quantitative Systems Pharmacology and Pharmacometric Model to Evaluate Effective Buprenorphine Induction Treatment Strategies in the Era of Synthetic Opioids
Celine Laffont
Favorite
Lanke, Shankar

Astrazeneca
(M-062) Successful Dose Optimization and Recommended Phase III Dose Determination of Saruparib (PARP1 Selective Inhibitor) Through MIDD and Comprehensive Quantitative Clinical Pharmacology
Shankar Lanke
Favorite
León, Cristhyne

Novadiscovery
(W-071) Mathematical modeling can help to successfully translate preclinical findings in mice models of asthma into first-in-human trials
Cristhyne León
Favorite
Lee, Dongjin

Amgen
(T-075) Enhancing Parameter Estimation Process for Pharmacokinetic-Pharmacodynamic Models with Meta-heuristic Optimization Approaches
Dongjin Lee
Favorite
Lee, Heekyung

University of Maryland School of Pharmacy
(T-076) Population Pharmacokinetic-Pharmacodynamic Modeling for Triapine to Optimize Dosing Regimen
Heekyung Lee
Favorite
Lee, Jaeyeon

Yuhan Corporation
(M-063) Population Pharmacokinetic/Pharmacodynamic Analysis of YH35995 for the First-in-Human Dose Prediction
Jaeyeon Lee
Favorite
Lee, Sooyoung

University of Maryland School of Pharmacy
(W-069) Exploring Appropriate Prior Distributions for Covariance Matrix Estimation in Bayesian Population Pharmacokinetic Analysis
Sooyoung Lee
Favorite
Leonov, Vladislav

InSysBio UK Ltd
(W-072) Unraveling Major Inflammatory Cytokines Serum Distribution Patterns in Systemic Lupus Erythematosus Patients: Insights from the CYTOCON Database
Vladislav Leonov
Favorite
Liao, Laura

Merck & Co., Inc
(M-065) Decoding Mean Viral Load in RSV Human Challenge Studies
Laura Liao
Favorite
Liao, Xiaozhi

UNC-Chapel Hill
(M-066) Optimizing Clinical Translation of Bispecific T Cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model
Xiaozhi Liao
Favorite
Lien, Yi Ting (Kayla)

Genentech Inc
(W-074) Exposure-response analyses of GO39932: a Phase Ia/b study of giredestrant in estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Yi Ting (Kayla) Lien
Favorite
Lim, Chay Ngee

Pfizer Inc., Cambridge, MA, USA
(W-075) Population pharmacokinetic modeling to support dose selection of rimegepant in pediatrics
Chay Ngee Lim
Favorite
Lindauer, Andreas

Calvagone SAS
(W-076) Interactive Pharmacometric Simulations and Model Exploration with e-Campsis
Andreas Lindauer
Favorite
(W-077) An Introduction to Campsis: The R-Based Open-Source PK/PD Simulation Suite
Andreas Lindauer
Favorite
Link, Kathryn

Pharmacometrics & Systems Pharmacology, Translational Clinical Sciences, Pfizer Inc
(T-079) A mechanistic QSP model of CRS allows for quantitative assessment of dose priming of CD3 bispecific antibody (BsAb) therapeutics.
Kathryn Link
Favorite
Li, Peizhi

the University of Iowa College of Pharmacy
(M-064) A semi-mechanistic pharmacometrics model to quantitatively characterize delta-9-tetrahydrocannabinol (THC) and its metabolites’ disposition among oral cannabis users
Peizhi Li
Favorite
Liu, Alan

Pfizer
(M-067) Stochastic Simulation and Estimation (SSE) for Design of Sample Size and Time Points in Pediatric Studies
Alan Liu
Favorite
Liu, Huan

Drug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, china
(T-080) A phase I open-label sequential clinical trial and population oral minimal model to study pharmacodynamic interactions of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity
Huan Liu
Favorite
Li, Xiaobin

GSK
(W-073) xplorer: a Flexible Shiny App for Data Visualization, Exploration and Quality Assurance
Xiaobin Li
Favorite
Li, Yisheng

University of Texas MD Anderson Cancer Center
(T-078) A Bayesian Semi-Mechanistic Dose-Finding Design for Phase I Drug Combination Trials in Oncology
Yisheng Li
Favorite
Li, Yuezhe

Metrum Research Group
(T-077) Quantitative Systems Pharmacology Modeling of Loncastuximab Tesirine Combined with Mosunetuzumab and Glofitamab Helps Guide Dosing for Patients with DLBCL
Yuezhe Li
Favorite
Long, Yuhan

University of Minnesota
(W-078) Effect of Convenience Sampling on Overall Drug Exposure during Pregnancy
Yuhan Long
Favorite
Lu, Dan

Genentech
(M-068) A translational QSP model to characterize the preclinical pharmacodynamics of combining a KRAS G12C inhibitor with a SHP2 inhibitor
Dan Lu
Favorite
Lumen, Annie

Clinical Pharmacology Modeling & Simulation, Amgen
(T-082) Optimizing Clinical Dosing Strategies to Mitigate Corneal Toxicity: Ocular PBPK Model-Based Evaluation of the Extent and Rate of Therapeutic Protein Distribution in the Human Cornea
Annie Lumen
Favorite
Luo, Dandan

Janssen Research & Development, LLC
(W-142) Population Pharmacokinetics and Exposure-response Analyses of Lazertinib in Combination with Amivantamab as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic NSCLC
Dandan Luo
Favorite
Lu, Yasong

Bicycle Therapeutics
(T-081) Application of Model Informed Drug Development (MIDD) to BT8009, a Bicycle Toxin Conjugate (BTC®), in Patients with Advanced Urothelial Cancer
Yasong Lu
Favorite
Lyu, Xintian

University of Minnesota
(W-079) Characterizing Pharmacokinetics Effects on Measures of Overall Drug Exposure during Pregnancy
Xintian Lyu
Favorite
M
MacDonald, Alexander

Allucent
(W-080) Comparison of common methodologies for accounting for IIV for oral bioavailability (F) in the absence of intravenous data
Alexander MacDonald
Favorite
Madrigal, Jamie

UNC Chapel Hill
(M-071) Mechanistic mathematical model of emicizumab
Jamie Madrigal
Favorite
Măgălie, Andreea

Merck & Co
(W-081) Quantifying dengue natural immunity and probability of disease using serum antibody titers
Andreea Măgălie
Favorite
Ma, Huilin

Bristol Myers Squibb
(T-083) Application of quantitative systems pharmacology modeling in reverse translation
Huilin Ma
Favorite
Mai, Tu

Genentech Inc.
(W-082) Population Pharmacokinetic and Exposure-Response Analyses of Alectinib and Its Metabolite M4 to Support Dose Selection in Patients with Resected Stage IB - IIIA ALK-Positive Non-Small Cell Lung Cancer
Tu Mai
Favorite
Mangal, Naveen

Gilead Sciences
(W-083) Model-based Meta-Analysis (MBMA) to Inform Immuotherapy (IO) Treatment Decisions in Metastatic Non-Small Cell Lung Cancer (mNSCLC)
Naveen Mangal
Favorite
Mapder, Tarunendu

Bristol Myers Squibb
(M-072) A shared pool modeling approach to describe antibody-mediated cell-cell interactions
Tarunendu Mapder
Favorite
Matteson, Andrew

Certara
(M-073) A Scalable Cloud-Based QSP Modeling System for Virtual Patient Generation
Andrew Matteson
Favorite
Matzuka, Brett

Regeneron Pharmaceuticals, Inc.
(T-026) A Semi-Mechanistic Population Pharmacokinetic (PopPK) Model of Linvoseltamab With Considerations of Disease-Related Factors in Patients (Pts) with Relapsed/refractory (RR) Multiple Myeloma (MM)
Brett Matzuka
Favorite
Ma, Xiaotang (Jessica)

Bristol-Myers Squibb
(M-070) Model Informed Drug Development (MIDD) Approach to Support Elzovantinib (TPX-022) Recommended Phase 2 Dose
Xiaotang (Jessica) Ma
Favorite
Mc Laughlin, Anna

Pharmetheus
(M-074) Exposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer
Anna Mc Laughlin
Favorite
McKnite, Autumn

University of Utah
(T-084) A COMBINED EX VIVO AND PHYSIOLOGICALLY-BASED PHARMACOKINETIC APPROACH TO INCORPORATE DRUG-DRUG INTERACTIONS FOR DOSING DURING CONTINUOUS RENAL REPLACEMENT THERAPY
Autumn McKnite
Favorite
Meaney, Cameron

Simulations Plus
(T-085) Modeling progression and treatment of mCRPC using the Thales QSP software platform
Cameron Meaney
Favorite
Mehrani, Ramin

Merck & Co Inc
(W-084) Exploring the feasibility of using AI to identify patient characteristics predictive of histological endpoints in metabolic dysfunction associated steatohepatitis (MASH)
Ramin Mehrani
Favorite
Mehta, Parsshava

University of Florida
(W-085) The Influence of Systematic and Technical Errors on Population Pharmacokinetic / Pharmacodynamic Model Parameters: Nonlinear Mixed-Effect Approach
Parsshava Mehta
Favorite
Mensing, Sven

AbbVie
(M-075) Leveraging Digital Biomarkers to Enhance Clinical Pharmacology and Pharmacometrics Informed Drug Development: A Case Study
Sven Mensing
Favorite
Mercier, Francois

Clinical Pharmacology, Genentech Inc., Basel, Switzerland
(T-016) Bridging the Gap: A Comprehensive Checklist for Hybrid Pharmacometrics-Machine Learning Model Building to Support Oncology Clinical Development
Francois Mercier
Favorite
Metelkin, Evgeny

InSysBio CY
(W-006) Application of identifiability analysis to obtain reliable parameters of the QSP model describing mechanism of action GEN1042 (BNT312) and acasunlimab
Evgeny Metelkin
Favorite
Milberg, Oleg

Regeneron Pharmaceuticals, Inc.
(M-076) Methodology of the Exposure-Response (E-R) Analysis of Linvoseltamab in Patients with Relapsed/Refractory (RR) Multiple Myeloma (MM)
Oleg Milberg
Favorite
Miyazawa, Kenji

Moderna, Inc.
(T-086) Development of a Whole-Body Physiologically Based Pharmacokinetics (PBPK) Model for Predicting Dynamics of mRNA and Protein for LNP-Encapsulated mRNA Therapeutics
Kenji Miyazawa
Favorite
Modi, Saurabh

Clinical Pharmacology Modeling and Simulation, Amgen Inc., South San Francisco, CA, USA
(W-086) Prediction of progression free survival using tumor growth inhibition models: Effect of model uncertainty, inter-individual variability and observational noise on prediction accuracy
Saurabh Modi
Favorite
Moein, Anita

Genentech, Inc.
(M-077) Population Pharmacokinetic Analysis of Fenebrutinib in Patients with Relapsing Multiple Sclerosis
Anita Moein
Favorite
Mohan, Krithika

GSK
(M-078) PKPD Modeling of PROTACs
Krithika Mohan
Favorite
Morales Junior, Ronaldo

Cincinnati Children's Hospital
(T-087) Population pharmacokinetics of cefepime in critically ill children and young adults
Ronaldo Morales Junior
Favorite
Morales, Juan

Critical Path Institute
(M-079) Advancing Drug Development Strategies in Progressive Supranuclear Palsy: A Model-based Clinical Trial Simulation Tool Approach
Juan Morales
Favorite
Mukker, Jatinder Kaur

EMD Serono, Billerica, MA, USA
(T-063) Advancing Modeling of Hematologic Safety using a Semi-mechanistic Multivariate PK/PD Approach: Application to the ATR Inhibitor Tuvusertib in Early Phase Oncology Development
Jatinder Kaur Mukker
Favorite
N
Na, Joo Young

The Ohio State University
(W-087) Comparison of empirical and physiologically-based modeling approaches to explore mechanisms of drug-drug interaction between abemaciclib and olaparib in a small cohort of patients with ovarian cancer
Joo Young Na
Favorite
Nakayama, Shinji

mitsubishi tanabe pharma corporation
(M-080) Development of a Simeprevir PBPK Model to Describe Changes in Coproporphyrin-I, an Endogenous OATP1B Biomarker, in Subjects with HCV
Shinji Nakayama
Favorite
Nazari, Fereshteh
(T-088) A Computational Modeling Framework to Provide a Feasibility Assessment, Inform Competitor Differentiation Strategy, Best-in-Class Properties, and Target Selection for Biologics Targeting IBD
Fereshteh Nazari
Favorite
Neumar, Christine

Certara USA, Inc.
(T-089) Integrated Population Pharmacokinetic Model of Bemnifosbuvir and Metabolites
Christine Neumar
Favorite
Ng, Chee Meng

NewGround Pharmaceutical Consulting LLC
(T-090) Whole-body Two-pore PBPK Model to Investigate the Disposition of Immunoglobulin M (IgM) in Mice
Chee Meng Ng
Favorite
(T-091) Fast Stepwise Selection Methods for Efficient Covariate Model Development in Population Data Analysis
Chee Meng Ng
Favorite
Nguyen, Hoa

Neurocrine Biosciences, Inc.
(M-081) Population Pharmacokinetic and Exposure-Response Analyses of Valbenazine in Patients with Huntington’s Disease Chorea
Hoa Nguyen
Favorite
Nie, Jing
(M-082) Integration of pharmacokinetics, safety, and efficacy into model-informed dose selection for Pimicotinib
Jing Nie
Favorite
Nieves, Emily

MIT, Delineate
(T-092) Delineate: a Literature Co-Pilot for Quantitative Systems Pharmacology
Emily Nieves
Favorite
Nikfar, Mehdi

Genmab
(M-083) Assessing Parameter Impacts on ADC Efficacy and Toxicity: Capabilities and Limitations of Sensitivity Analysis in an Innovative Full Physiologically Based Pharmacokinetic Pharmacodynamic Framework
Mehdi Nikfar
Favorite
Niloy, Kumar Kulldeep

Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital
(T-093) Preclinical tumor growth inhibition modeling and simulation to support dosing regimen selection of a novel EWS-FLI1 inhibitor for Ewing sarcoma treatment
Kumar Kulldeep Niloy
Favorite
O
O'Brien, Grace

Metrum Research Group
(W-088) pmparams: an R Package for Defining and Formatting Parameter Tables in Pharmacometric Modeling
Grace O'Brien
Favorite
Oh, Elise

Gilead Sciences, Inc.
(W-089) Modeling Lenacapavir (LEN) Exposure After Daily Oral Administration Alone and in Combination with Bictegravir (BIC) in People with HIV: A Population Pharmacokinetic Approach
Elise Oh
Favorite
Okada, Hiroki

Kyowa Kirin, Inc.
(M-084) Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Burosumab in Patients with X-Linked Hypophosphatemia Aged <12 Months
Hiroki Okada
Favorite
(M-085) PBPK-mQSP Model Analysis of KHK4951, an Eye Drop Formulation of Tivozanib, a Potent and Selective VEGF Receptor Inhibitor
Hiroki Okada
Favorite
Oka, Takaaki

Daiichi Sankyo Co., Ltd.
(T-094) Cellular and Humoral Semi-mechanistic Immune Response Models of a Vaccine Candidate for Respiratory Syncytial Virus Infection
Takaaki Oka
Favorite
Oladoyinbo, Olayide

Pfizer Canada
(M-086) Population Pharmacokinetic (Pop PK) Modeling of Nirmatrelvir/Ritonavir in Severe Renal Impaired Participants with COVID-19 either on or not on Hemodialysis
Olayide Oladoyinbo
Favorite
Osawa, Mayu

Bristol Myers Squibb
(M-087) Model Platform to Predict Long-Term Clinical Outcome for Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
Mayu Osawa
Favorite
P
Paleja, Bhairav

Vantage Research
(T-010) A quantitative systems pharmacology model framework for combined clinical efficacy and hematological toxicity predictions for antibody drug conjugates
Bhairav Paleja
Favorite
Panetta, John

St Jude Children's Research Hospital
(M-088) Modeling Effects of Dose, Schedule, and Pharmacokinetics of Fludarabine Lymphodepletion Therapy on CAR T-cell and Cytokine Dynamics
John Panetta
Favorite
Papadopoulos, Stefanos

University of Pittsburgh
(T-095) Modeling the Role of Organ Crosstalk and Cellular Adaptation in Multiple Organ Dysfunction Syndrome
Stefanos Papadopoulos
Favorite
Parikh, Sanjana

College of Pharmacy University of Cincinnati, Cincinnati Children's Hospital Medical Center
(W-090) Physiologically Based Pharmacokinetic Model of Vedolizumab in Adult Patients with Inflammatory Bowel Disease
Sanjana Parikh
Favorite
Paris, Alessio

Fondazione The Microsoft Research - University of Trento Centre for Computational and Systems Biology (COSBI), Rovereto, Italy
(T-096) Integrating Motor Function Scores of Spinal Muscular Atrophy in a Quantitative Systems Pharmacology Model of Neurofilament
Alessio Paris
Favorite
Parker, Robert

Departments of Chemical and Petroleum Engineering and Critical Care Medicine; University of Pittsburgh
(T-097) Model Predictive Control Regulates Blood Pressure During Simulated Kidney Replacement Therapy
Robert Parker
Favorite
Park, Hyunseo

UTHSC, College of Pharmacy
(W-091) Characterization of the Effect of Biofilm Formation on the Antimicrobial Activity of Tigecycline against M. abscessus using a Hollow Fiber Infection Model and Pharmacokinetic/Pharmacodynamic Modeling
Hyunseo Park
Favorite
Park, Seongwon

Chungnam National University
(W-028) Development and application of physiologically based pharmacokinetic model of darunavir on pregnant population
Seongwon Park
Favorite
(W-093) Integration of Population Pharmacokinetic Model for Tenofovir Alafenamide by External Evaluation
Seongwon Park
Favorite
Park, Taeshin

RES Group Inc
(W-092) Incorporating Computational Fluid Dynamic Modeling into Pharmacometrics Models for Applications to Gene Therapy, Anti-Inflammatory Treatments and Transdermal Patch Drug Delivery
Taeshin Park
Favorite
Park, Wansu

Alnylam Pharmaceuticals
(W-094) Population Pharmacokinetic/Pharmacodynamic Analysis of Cemdisiran (ALN-CC5) in Healthy Subjects and Patients with Immunoglobulin A Nephropathy
Wansu Park
Favorite
Patidar, Krutika

University at Buffalo
(M-089) A minimal PBPK model to study the effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody PK
Krutika Patidar
Favorite
Pendse, Salil

Allucent
(W-095) Physiologically Based Pharmacokinetic (PBPK) modeling of hepatic impairment using PK-Sim
Salil Pendse
Favorite
Pichardo, Cesar

Systems Medicine, Clinical Pharmacology & Quantitative Pharmacology, R&D BioPharmaceuticals, AstraZeneca, Cambridge, UK
(W-096) Quantitative Systems Pharmacology of T-cell Engagers and Cytokine Release
Cesar Pichardo
Favorite
Pillai, Nikhil

Sanofi
(W-097) Predicting pharmacokinetic profile of small molecule drugs based on chemical structure using machine learning.
Nikhil Pillai
Favorite
Piscitelli, Joseph

Pfizer Inc., La Jolla, CA, USA
(T-098) Population pharmacokinetic modeling of Binimetinib in Healthy Volunteers and Participants with BRAF V600-mutant or NRAS-mutant Solid Tumors
Joseph Piscitelli
Favorite
Poels, Kamrine

Pfizer
(W-098) Role of quantitative systems pharmacology (QSP) in optimizing elranatamab dosing regimen for relapsed/refractory multiple myeloma
Kamrine Poels
Favorite
Poland, Bill
(T-099) Acoramidis (ALXN2060) Population Pharmacokinetic Modeling and the Importance of Exploring Categorization of Covariate Values
Bill Poland
Favorite
Poon, Victor

Genentech
(W-099) Constructing a virtual control arm and evaluating operating characteristics using TGI metrics to support go/no-go decisions for single-arm Phase Ib/II combination studies
Victor Poon
Favorite
Pourzanjani, Arya

Amgen
(M-090) A Novel Approach to Capturing the Dynamics of Nontarget and New Tumors in Mechanistic Models of Progression-Free Survival
Arya Pourzanjani
Favorite
(M-091) Fully Bayesian Covariate Selection in Population Pharmacokinetics and Pharmacodynamics Models Using Regularized Horseshoe Priors
Arya Pourzanjani
Favorite
Purohit, Prasad
(M-092) Integrated Quantitative Systems Pharmacology and Pharmacometric Model to Evaluate Effective Buprenorphine Induction Treatment Strategies in the Era of Synthetic Opioids
Prasad Purohit
Favorite
Q
Quinlan, Lauren

Critical Path Institute
(M-093) Challenges in curating Real World Data for modeling: A Bronchopulmonary Dysplasia case study
Lauren Quinlan
Favorite
R
Rachid, Ousama

College of Pharmacy, QU Health, Qatar University, Doha, Qatar
(W-009) A Physiological-Based Pharmacokinetic (PBPK) Model embedded with Pulmonary Compartmental Absorption and Transit (PCAT™️) Module to Predict Intranasal Ketamine Pharmacokinetics in Pediatric Population
Ousama Rachid
Favorite
Ramakrishnan, Vidya

Genentech, Inc.
(M-095) Population Pharmacokinetic Modeling Informed the Dose of GDC-8264 for a Phase 1b Study in Participants with Acute Graft-Versus-Host Disease
Vidya Ramakrishnan
Favorite
Rao, Rohit

Pfizer
(T-101) A QSP model of atopic dermatitis to accelerate the clinical translation of novel combination therapies
Rohit Rao
Favorite
Rao, Satyajit

Novartis
(T-100) Beyond Subcutaneous Dosing: Efficiency of liver-targeting siRNAs dosed via alternates routes and formulations.
Satyajit Rao
Favorite
Rashid, Jahidur

Vertex Pharmaceuticals, Inc.
(T-019) Simulate modified Nonmem models using NMsim
Jahidur Rashid
Favorite
Ratushny, Alexander

Bristol Myers Squibb
(W-059) Facilitating RP2D decisions for CAR T cell therapy clinical studies using a QSP model
Alexander Ratushny
Favorite
Ravula, Abhigyan

EMD Serono
(W-100) Pharmacometrics-Based Evaluation of Fixed versus Weight-Based Dosing Strategies for Approved Antibody Drug Conjugates (ADC)
Abhigyan Ravula
Favorite
Ray, Ashley

University of Georgia
(T-102) Redefining Multidrug Resistance Quantitatively using Live Cell Functional Data
Ashley Ray
Favorite
Rebello, Juliet

Symbiosis International University, Pune
(W-101) Development of a Population PK model for an inhaled drug
Juliet Rebello
Favorite
Reed, Michael
(W-102) Mathematical optimization of a thrombopoiesis quantitative systems pharmacology (QSP) model
Michael Reed
Favorite
Reilly, Brian

Vertex Pharmaceuticals
(T-103) A model-based simulation workflow enables automated and accurate generation of clinical pharmacology summary statistics, a workflow and case-study.
Brian Reilly
Favorite
Renardy, Marissa

Certara
(M-025) A quantitative systems pharmacology (QSP) model to enable prediction of ARIA-E incidence with anti-Aβ monoclonal antibody therapies for Alzheimer’s disease
Marissa Renardy
Favorite
Reynaldo Fernandez, Gledys

College of Pharmacy, University of Florida
(W-103) Prediction of the Biological Effect of PEG-rHuEPO Candidates in Chronic Kidney Disease Patients using a Middle-out Translation Approach
Gledys Reynaldo Fernandez
Favorite
Richfield, Owen

Yale University
(W-104) Modeling Endothelial Cell-Targeted Polymeric Nanoparticle Delivery in Renal Glomeruli
Owen Richfield
Favorite
Rieger, Theodore

Pfizer
(T-104) Adaptation of the Glucose, Glucagon, Gastric-Inhibitory Peptide, Glucagon-like Peptide-1, and Insulin (4GI) Model for Simulation of Acute Meal Challenges with Infused Antagonists
Theodore Rieger
Favorite
Ruiz-Martinez, Alvaro

Rosa & Co. LLC
(W-102) Mathematical optimization of a thrombopoiesis quantitative systems pharmacology (QSP) model
Alvaro Ruiz-Martinez
Favorite
Ryman, Josiah

EMD Serono
(W-105) Informing Early Trial Design in Oncology Through Clinical Trial Simulations from Population Pharmacokinetic-Tumor Growth Inhibition Models
Josiah Ryman
Favorite
Ryu, Hyunwook

Seoul National University College of Medicine and Hospital
(M-096) Population pharmacokinetics analysis of DA-8010, a novel anti-muscarinic agent
Hyunwook Ryu
Favorite
S
Sachs, Jeffrey

Quantitative Pharmacology and PMX, Merck & Co., Inc., USA
(W-106) Comparing Predicted Serotype-specific Vaccine Effectiveness of Pneumococcal Conjugate Vaccines V114 and PCV20 in Children using a novel model-based meta-analysis approach
Jeffrey Sachs
Favorite
Sale, Mark

Integrated Drug Development, Certara Inc.
(M-097) Automatic differentiation, a possible solution to numerical instability in Population PK parameter estimation
Mark Sale
Favorite
Salian, Vrishali

Department of Pharmaceutics, University of Minnesota-Twin Cities
(T-105) Generating data-driven insights from the Alzheimer’s Disease Neuroimaging Initiative (ADNI): Towards establishing a QSP model of Alzheimer’s disease
Vrishali Salian
Favorite
Salimgareev, Ruslan

Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University
(W-107) Mechanistic Modeling Of Surface Molecule Interactions: Impact Of Methodology On CAR-T Cell Dose Predictions
Ruslan Salimgareev
Favorite
Salinger, David

Certara, Inc.
(M-098) Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK of participants with Mycobacterium tuberculosis
David Salinger
Favorite
Sandefur, Conner

Simulations Plus Inc
(T-106) Simulated CD8+ T Cell-Mediated Liver Injury During Ipilimumab Administration in a Simulated Population (SimPops®) Demonstrates Profiles Consistent with Observed Clinical Data
Conner Sandefur
Favorite
Saqr, Abdelrahman

University of Minnesota
(W-108) Incorporating High Dimensional Gut Microbiome Data into Population Pharmacokinetic Modeling of Mycophenolate Mofetil
Abdelrahman Saqr
Favorite
Sayama, Hiroyuki

Nonclinical Biomedical Science, Astellas Pharma Inc.
(T-107) Comprehensive Human Quantitative Systems Pharmacology Models for Immuno-Oncology: Enhancing Decision-Making on Target Indications and Combination Strategies for New Drug Development
Hiroyuki Sayama
Favorite
Schaller, Stephan

ESQlabs GmbH
(T-050) A review of OSP suite PBBM capabilities: looking ahead
Stephan Schaller
Favorite
Scheuher, Bruna

Takeda
(T-088) A Computational Modeling Framework to Provide a Feasibility Assessment, Inform Competitor Differentiation Strategy, Best-in-Class Properties, and Target Selection for Biologics Targeting IBD
Bruna Scheuher
Favorite
Schiavone, Carmine

University of Naples "Federico II"
(T-035) Identifying Determinants of Vaccine Efficacy: A Mechanistic Modeling Approach
Carmine Schiavone
Favorite
Shahinuzzaman, Md

AstraZeneca
(W-109) Comparative Analysis of Minimal Physiologically Based Pharmacokinetic (mPBPK) and Traditional Pharmacokinetic (PK) Models in the Context of Quantitative Systems Pharmacology (QSP) for T-cell Engagers
Md Shahinuzzaman
Favorite
SHAH, ZEEL

Bristol Myers Squibb
(M-099) Advancing Drug Development in Relapsed and Refractory Multiple Myeloma (RRMM): Assessing the Safety and Efficacy Landscape Utilizing Model-Based Meta-Analysis
ZEEL SHAH
Favorite
Shaik, Jafar Sadik

Johnson & Johnson
(W-110) PK/PD Modeling of the Anti-FcRn Monoclonal Antibody Nipocalimab Administered to Healthy Subjects and Participants with Moderate to Severe Active Rheumatoid Arthritis
Jafar Sadik Shaik
Favorite
SHAO, SHUAI

Sanofi
(T-108) Comparison of NONMEM and AI-Based Approaches for Population Pharmacokinetic Simulations to Support Model-Informed Drug Development
SHUAI SHAO
Favorite
(T-109) Model-Based Analysis of Pharmacokinetics of Venglustat, a small-molecule inhibitor of glucosylceramide synthase, Using Pooled Data from Healthy Subjects and Patients with Lysosomal Storage Disorders
SHUAI SHAO
Favorite
Shapiro, Monica

Pfizer
(M-100) A Quantitative Systems Pharmacology Model of LNP-mRNA Uptake Through LDLR Binding
Monica Shapiro
Favorite
Sheehan, Robert

Rosa & Co. LLC
(W-034) Parallel Tempering for Generation of Virtual Patients and Virtual Populations
Robert Sheehan
Favorite
Shelly, Iris

NTT Research, Inc.
(M-101) Cardiovascular Model Parameterization of Digital Twins for Acute Care Drug Delivery: An Iterative Bayesian Approach
Iris Shelly
Favorite
Shenkoya, Babajide

University of Maryland Baltimore
(W-111) Pharmacokinetics of Long-Acting Naltrexone in Pregnancy: Insights from Physiologically Based Pharmacokinetic Modeling
Babajide Shenkoya
Favorite
Shi, Jian

BMS
(W-112) Use of Model-Informed Drug Development (MIDD) to Support Dose Selection of Nivolumab in Combination with Ipilimumab in Adolescent Patients with MSI-H/dMMR Metastatic Colorectal Cancer
Jian Shi
Favorite
(W-113) Population Pharmacokinetic and Exposure-Response Analyses of Nivolumab in Combination with Ipilimumab to Support Dosing Regimen in Subjects with First-Line MSI-H/dMMR Metastatic Colorectal Cancer
Jian Shi
Favorite
Shin, Euibeom

University at Buffalo school of pharmacy and pharmaceutical science
(M-103) Evaluation of ChatGPT and Gemini large language models for pharmacometrics with NONMEM
Euibeom Shin
Favorite
(M-104) Evaluation of prompt engineering strategies for pharmacokinetic data analysis with the ChatGPT large language model
Euibeom Shin
Favorite
Shi, Yufei

Fudan University
(M-102) Population Pharmacokinetics and Exposure-Response Analysis of Birociclib Plus Fulvestrant in Advanced Breast Cancer Patients
Yufei Shi
Favorite
Shroff, Sanaya

Vertex Pharmaceuticals
(T-110) Simulation of Trial Predictions with Model Uncertainty using NMsim
Sanaya Shroff
Favorite
Siripuram, Vijay

Astellas Pharma
(W-114) Consideration of Study design aspects in the creation of virtual populations for organ impairment studies: One size may not fit all
Vijay Siripuram
Favorite
Skataric, Maja

Novartis
(W-137) Immune thrombocytopenia purpura (ITP) indication extension allowing for administration of Eltrombopag in adult patients who are refractory to 1L-treatment irrespective of time since diagnosis
Maja Skataric
Favorite
Soliman, Amira

Center for Pharmacometrics & Systems Pharmacology
(W-115) Leveraging PBPK modeling to advance spironolactone complex disposition knowledge
Amira Soliman
Favorite
Song, Eric

Genmab US, Inc.
(T-112) Application of Machine Learning Methods to Predict Risk of Adverse Events in Clinical Trials
Eric Song
Favorite
Sorribes, Inmaculada

Quantitative Pharmacology and Pharmacometrics Immune/Oncology (QP2-I/O), Merck & Co., Inc., Rahway, New Jersey, USA
(W-116) Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)
Inmaculada Sorribes
Favorite
Soufsaf, Sara

Syneos Health
(W-117) PMXModelStructuR: A Tool for Pharmacometrics Model Visualization in R
Sara Soufsaf
Favorite
Spinosa, Phillip

Genentech, Inc.
(T-113) QSP model trained on preclinical data informs clinical dose selection for a T-cell engaging bispecific antibody for solid tumor indications
Phillip Spinosa
Favorite
Stadt, Melissa

University of Waterloo
(M-105) Sex differences in patients with chronic kidney disease: A quantitative systems pharmacology modeling study
Melissa Stadt
Favorite
Stephens, Hunter

Certara
(M-106) A Model-Informed Drug Development Framework for the Development and Dose Optimization of Targeted Radiation Therapies
Hunter Stephens
Favorite
Sukumar, Prema

Bristol Myers Squibb
(T-114) SAS Macro for Validation of NONMEM Data Items Pertaining to Implicit Expansion of Dose Records in Oral Dose Population Pharmacokinetic Datasets
Prema Sukumar
Favorite
Sunkaraneni, Soujanya

Syndax Pharmceuticals, Inc., Walthman, MA
(W-119) Population pharmacokinetics of revumenib in patients with relapsed/refractory acute leukemias
Soujanya Sunkaraneni
Favorite
Sun, Kefeng

Takeda Development Center Americas Inc
(M-107) Physiologically-Based Pharmacokinetic Modeling of Maribavir Incorporating Metabolism by Cytochrome P450, Glucuronidation, and Hepatic Uptake, for Prediction of Victim Drug-Drug Interaction Potentials
Kefeng Sun
Favorite
Sun, Steven

UCSD
(W-118) Evaluation of the population pharmacokinetics of pexmetinib in a simultaneous model of two formulations
Steven Sun
Favorite
T
Takaichi, Daisuke

Kyowa Kirin Co., Ltd
(W-120) Quantitative Systems Pharmacology Modeling of X-linked Hypophosphatemia Disease Pathway Normalization to Predict the Impact of Burosumab Treatment on Serum Biomarkers in Adult and Pediatric Patients
Daisuke Takaichi
Favorite
Takenaka, Misako

GlaxoSmithKline
(M-108) How should we leverage prior adult knowledge for pediatric PK analysis? - A case study comparing Pooled and Bayesian population PK approaches
Misako Takenaka
Favorite
Tang, Zoey

AstraZeneca
(W-122) Dual Target-Mediated Drug Disposition Model to Guide the Selection of Starting Dose and Escalation in FTIH Trials for Volrustomig (MEDI5752), a Monovalent Bispecific Antibody Targeting PD-1 and CTLA-4
Zoey Tang
Favorite
(W-123) Population pharmacokinetic analysis of Dato-DXd, a TROP2-targeting ADC, in NSCLC and HR-positive, HER2-negative breast cancer patients
Zoey Tang
Favorite
Tania, Nessy

Pfizer Research and Development
(M-109) Advancing Quantitative Systems Pharmacology Model for Inflammatory Bowel Disease for Clinical Efficacy Predictions in Ulcerative Colitis
Nessy Tania
Favorite
Tan, Wen Rui

Cincinnati Children's Hospital Medical Center
(W-121) Model-informed simulations to determine optimal Piperacillin-Tazobactam Dosing regimens in Pediatric Perioperative Care: Effect of body size and renal function
Wen Rui Tan
Favorite
Tao, Mengdi

Sanofi US
(T-115) Approaches for Developing a Robust Virtual Twin Workflow in Quantitative Systems Pharmacology Models
Mengdi Tao
Favorite
Tarek, Mohamed

Pumas-AI Inc., USA
(T-116) A DeepNLME-based Tumor Growth Dynamics and Overall Survival Model for Non Small Cell Lung Cancer
Mohamed Tarek
Favorite
Taylor, Adekemi

Certara Inc.
(M-137) A Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Model for Covalent Bruton Tyrosine Kinase Inhibitor TL-895
Adekemi Taylor
Favorite
Taylor, Zachary

Cincinnati Children's Hospital Medical Center
(T-117) A High-Dose Methotrexate Dashboard: Integrating MTXPK.org into the Electronic Health Record to Facilitate Model-Informed Care for Pediatric Patients with Malignant Conditions
Zachary Taylor
Favorite
Templeton, Ian

Certara; Simcyp Consultancy Division
(W-124) Real world examples of PBPK impact on CYP3A4 victim DDI drug label content
Ian Templeton
Favorite
Tendolkar, Amol

Bristol Myers Squibb
(T-118) Population Pharmacokinetic and Exposure-Response Analyses of Neoadjuvant Nivolumab plus Chemotherapy, followed by Adjuvant Treatment with Nivolumab in Subjects with Resectable Stage II-IIIB NSCLC
Amol Tendolkar
Favorite
THE UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER, Paridhi

Department of Pharmaceutical Sciences, University of Tennessee Health Science Center
(T-051) Mechanistic model-based analysis of Total IgG kinetics and pathogenic autoantibody pharmacodynamics in autoimmune diseases
Paridhi THE UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER
Favorite
(T-052) Modeling the Time-Varying Impact of Anti-Drug Antibody Formation on the Pharmacokinetics of a Human Monoclonal Antibody in a Preclinical Study
Paridhi THE UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER
Favorite
THIBAULT GREUGNY, Elea

Novadiscovery
(M-006) An innovative paradigm for non-small cell lung cancer clinical trial simulations through the Integration of a quantitative systemic pharmacology model and pharmacodynamic model of gemcitabine
Elea THIBAULT GREUGNY
Favorite
(M-007) Leveraging AI for improved reproducibility of mathematical disease models: insights from a retinitis pigmentosa case study
Elea THIBAULT GREUGNY
Favorite
Thomas, Haryana Yosef

University at Buffalo
(M-110) A quantitative systems pharmacology model for diabetes-induced glomerular fibrosis
Haryana Yosef Thomas
Favorite
tian, zhiteng

Drug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China
(T-119) Development of a Population Pharmacokinetic Model for Ganciclovir to Assess the Renal Impairment Impact in Chinese Patients
zhiteng tian
Favorite
Tobin, Kevin

Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, MD
(W-125) Flux-based IVIVC for predicting oxybutynin exposure with and without occlusion of a transdermal gel
Kevin Tobin
Favorite
(W-126) Population Pharmacokinetics of Atomoxetine at Steady-State Dosing for ADHD Treatment in Children and Adolescents
Kevin Tobin
Favorite
Tong, Dominic

InsightRX
(M-111) Cystatin C complements but does not exceed serum creatinine as a renal function marker: evidence from vancomycin pharmacokinetic model performance in a clinical context
Dominic Tong
Favorite
Tong, Xiao

Pharmacometrics, Quantitative Clinical Pharmacology & Biosimilars, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA
(W-127) Population pharmacokinetic and pharmacodynamic modeling of free serum interleukin-15 in response to TEV-53408, an anti-interleukin 15 monoclonal antibody, in healthy volunteers.
Xiao Tong
Favorite
Toyoshima, Junko

Astellas Pharma Global Development, Inc.
(M-112) Evaluation of Praziquantel Exposures in Children Dosed Using Different Body Weight Estimation Methods
Junko Toyoshima
Favorite
Trame, Mirjam

Certara
(M-113) Oncology MIDD Simulator, A User-Friendly Application for Overall Survival Forecasting in Early Oncology Trials
Mirjam Trame
Favorite
Tran, Brittany

Daiichi Sankyo, Inc.
(W-128) Population pharmacokinetics and exposure-safety of DS-6157a in patients with advanced gastrointestinal stromal tumor (GIST)
Brittany Tran
Favorite
Trogdon, Michael

Pfizer
(M-114) Virtual clinical trial simulations using a Quantitative Systems Pharmacology (QSP) model of CDK inhibitors in breast cancer patients
Michael Trogdon
Favorite
Tummala, Hari Prabhath

University of California, San Francisco
(T-120) Assessing Sirolimus and Antiretroviral Interactions in People with HIV on Chronic ART: A Population Pharmacokinetic Approach in Non-Transplant Recipients
Hari Prabhath Tummala
Favorite
U
Umetsu, Yuko

Eisai Co., Ltd.
(M-115) Population Pharmacokinetic and Exposure-Response Analyses of Tasurgratinib in Subjects with Unresectable Advanced or Metastatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Gene Fusion
Yuko Umetsu
Favorite
V
Valerie Sia, Jie En

Drug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China
(W-129) Frailty phenotype as a sensitive indicator of aging-related Cytochrome P450 3A functional changes：Application of dose optimization recommendations for ticagrelor in the Chinese frail older population
Jie En Valerie Sia
Favorite
Vallejo, Celeste

Simulations Plus
(W-130) Physiologically Based Pharmacokinetic Models for Infliximab, Ipilimumab, and Nivolumab Developed with GastroPlus® to Predict Hepatic Concentrations
Celeste Vallejo
Favorite
van der Walt, Jan-Stefan

Occams Cooperatie U.A.
(T-121) Joint bi-directional PK-ADA population modelling in immuno-oncology
Jan-Stefan van der Walt
Favorite
Van Schaick, Erno

Calvagone SAS
(W-076) Interactive Pharmacometric Simulations and Model Exploration with e-Campsis
Erno Van Schaick
Favorite
Verma, Meghna

AstraZeneca
(T-122) A Quantitative Systems Pharmacology Approach to Understand the Variability of Patient Response to T-cell Bi-specifics in Hematological Malignancies
Meghna Verma
Favorite
Vollmer, Jannik

LYO-X AG, Basel, Switzerland
(T-123) Monte-Carlo simulations to assess the probability of target attainment for cefepime and enmetazobactam in patients with complicated urinary tract infections
Jannik Vollmer
Favorite
(T-124) Translational modelling from preclinical data to predict human PK of monoclonal antibodies with engineered FcRn binding
Jannik Vollmer
Favorite
VU, NGOC-ANH THI

College of Pharmacy, Chungnam National University, Daejeon 34134, South Korea.
(T-125) Beyond the Michaelis-Menten: Evaluation of Novel IVIVE Approach for Predicting In Vivo Intrinsic Clearance from Hepatocyte Assays
NGOC-ANH THI VU
Favorite
W
Wang, Angelia

J&J Innovative Medicine
(M-117) Semi-mechanistic modeling to investigate differential dynamics of anti-citrullinated protein antibody (ACPA) IgG versus total IgG reduction following nipocalimab treatment
Angelia Wang
Favorite
Wang, Bing

Amador Bioscience
(W-132) Population Pharmacokinetic Modeling of IMP7068 in Patients with Advanced Solid Tumors
Bing Wang
Favorite
Wang, Bonnie

Bristol Myers Squibb
(M-118) Past as Prologue: A Novel Anti-Fucosyl-GM1 Monoclonal Antibody in Extended Stage Small Cell Lung Cancer (ES-SCLC) Phase 3 Dose Selection through Exposure/Dose-Response Analyses of Efficacy and Safety
Bonnie Wang
Favorite
(M-119) Population Pharmacokinetic (popPK) of BMS-986012, a Novel Anti-Fucosyl-GM1 Monoclonal Antibody, in Patients with First-Line and Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Bonnie Wang
Favorite
Wang, Chen

ClinPharm
(M-082) Integration of pharmacokinetics, safety, and efficacy into model-informed dose selection for Pimicotinib
Chen Wang
Favorite
Wang, Guanyu

Vertex Pharmaceuticals
(T-126) Quantification of uncertainty in human dose predictions
Guanyu Wang
Favorite
Wang, Jin

AbbVie Inc.
(T-127) Surface plasmon resonance enabled mechanistic pharmacokinetic/pharmacodynamic modeling to support covalent inhibitor drug development: Bruton’s tyrosine kinase inhibitor case study
Jin Wang
Favorite
Wang, Qi

Enliven Therapeutics
(T-128) Application of PKPD Principles to Drive the Discovery and Development of Novel BCR-ABL Tyrosine Kinase Inhibitors
Qi Wang
Favorite
Wang, Yuchen

Pfizer Inc.
(M-116) Approaches of Incorporating Prior Information in Pediatric PopPK Model Development with Limited Data
Yuchen Wang
Favorite
Wan, Mike

Gilead Sciences
(W-131) Mechanistic modeling to inform T cell engager development for low copy targets
Mike Wan
Favorite
Wei, Tracey
(W-049) Exposure-Response Analysis for Hepatotoxicity of Rivoceranib Monotherapy and in Combination with Camrelizumab in Patients with Various Cancers, Including Advanced Hepatocellular Carcinoma
Tracey Wei
Favorite
Wieler, Annaliese

Metrum Research Group
(W-012) Reinforcement Learning for Pharmacometrics: A Proof of Concept and Future Directions
Annaliese Wieler
Favorite
Wiens, Matthew

Metrum Research Group
(W-133) Losing the Forest: Causal Shapley Additive Explanations for Interpretation of Population-Pharmacokinetic models
Matthew Wiens
Favorite
Woodhead, Jeff

Simulations Plus
(M-120) Quantitative Systems Toxicology Modeling of Otenaproxesul Liver Enzyme Elevations Leads to Prediction of Liver Safety for Acute Otenaproxesul Dosing
Jeff Woodhead
Favorite
Woo, Laura

Bristol Myers Squibb
(T-129) A prototype mechanistic systems pharmacology model of Type 2 interventions in eosinophilic esophagitis
Laura Woo
Favorite
Wu, Fan

Bristol Myers Squibb
(M-138) Population cellular kinetics of idecabtagene vicleucel in patients with triple-class-exposed relapsed/refractory multiple myeloma
Fan Wu
Favorite
Wu, Yujie

Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China
(T-130) Development of the second-generation PBPK model to quantify OATP1B, P-gp, BCRP transporter and CYP3A4 enzyme activity changes for Chinese ESRD patients
Yujie Wu
Favorite
X
Xia, Huiming

BMS
(M-121) Population Pharmacokinetics and Exposure-Response Analysis Supports Phase 2 Dose Selection for BMS-986288, a non-fucosylated anti-CTLA4 antibody Prodrug
Huiming Xia
Favorite
Xiao, Dan

Merck & Co., Inc.
(M-122) Overcome the Challenges of NONMEM PopPK Dataset for Late Stage Daily Dose Study
Dan Xiao
Favorite
Xu, Christine

Sanofi
(M-123) Streamlining Dupilumab Nasal Polyposis Clinical Development Strategy: Leveraging Modeling and Biomarker Bridging for the Phase 3 Dose Selection
Christine Xu
Favorite
(M-124) Physiologically-based pharmacokinetic modeling approach to support eliglustat development for pediatric patients with Gaucher disease
Christine Xu
Favorite
Xu, Min

The University of Iowa
(M-125) Explore the Impact of Pharmacological Target-Mediated Low Plasma Exposure in Lead Compound Selection in Drug Discovery – a Modeling Approach
Min Xu
Favorite
Xu, Qiushuang (Rachel)

Critical Path Institute
(T-131) A Bayesian Model-based CTS Tool to Optimize Clinical Trial Design in Duchenne Muscular Dystrophy
Qiushuang (Rachel) Xu
Favorite
Xu, Shuang

Certara, Inc.
(T-132) Impacts of dose titration on logistic exposure-response in simulated flexible-dose clinical trials
Shuang Xu
Favorite
Xu, Siyan

Novartis Pharmaceuticals
(W-134) Causal directed acyclic graph (DAG) application in exposure-response analyses
Siyan Xu
Favorite
Y
Yan, Diqin

Clinical Trial Institution, Peking University People's Hospital
(T-133) Placebo Response Model for Alopecia Areata: A Model-based Meta-analysis of Randomized Controlled Trials
Diqin Yan
Favorite
Yang, Feng

Astrazeneca
(W-135) PharmaInsight Explorer: Empowering EDA in Clinical Pharmacology and Safety Science
Feng Yang
Favorite
Yang, Janice

Icahn School of Medicine at Mount Sinai
(M-127) Creating Cell-specific Computational Models of Stem Cell-derived Cardiomyocytes Using Optical Experiments
Janice Yang
Favorite
Yang, Tae Eun

Johnson & Johnson Innovative Medicine
(M-128) Population Pharmacokinetic Analysis of Guselkumab in Adults with Moderately to Severely Active Crohn’s Disease
Tae Eun Yang
Favorite
Yang, Xinxin

Bristol Myers Squibb
(M-129) Automating Translational Physiologically Based Pharmacokinetic Modeling with R and Simcyp: An Innovative Approach
Xinxin Yang
Favorite
Yan, Xiaoyu

The Chinese University of Hong Kong
(M-032) A Whole-body Mechanistic Physiologically-based Pharmacokinetic Modeling of Intravenous Iron
Xiaoyu Yan
Favorite
(M-126) A mechanism-based pharmacokinetic/pharmacodynamic model for iron-regulated hematopoietic stem and progenitor cells commitment towards erythroid and megakaryocyte lineages
Xiaoyu Yan
Favorite
Yellepeddi, Venkata

Division of Clinical Pharmacology, Spencer Fox Eccles School of Medicine, University of Utah
(T-134) Integrating Physiologically Based Pharmacokinetic (PBPK) Modeling and Strain-Specific Exposure-Efficacy Requirements to Refine the Dosage Regimens for Voriconazole in a Pediatric Cancer Population
Venkata Yellepeddi
Favorite
Yin, Xuefen

University of Florida
(T-135) Potential Bias Evaluation of Conventional Exposure-Response Analysis Methods: A Small Molecule Cancer Drug Example
Xuefen Yin
Favorite
Yoder, Todd

Metrum Research Group
(W-136) Gompertz Cure Rate Survival Models with Stan and Brms
Todd Yoder
Favorite
Yoon, Deok Yong

Novartis
(W-137) Immune thrombocytopenia purpura (ITP) indication extension allowing for administration of Eltrombopag in adult patients who are refractory to 1L-treatment irrespective of time since diagnosis
Deok Yong Yoon
Favorite
Yuan, Dongfen

Janssen Research & Development
(M-132) Population Pharmacokinetics and Exposure-Response Relationship of Amivantamab in Combination with Carboplatin-Pemetrexed: Analyses from PAPILLON Supporting the Weight-Tiered Q3W Regimen
Dongfen Yuan
Favorite
Yuan, Lin

Fractal Therapeutics
(W-138) A model-based framework for assessing schedule dependence of therapeutic window for three-drug combinations
Lin Yuan
Favorite
(W-139) Design and evaluation of a novel decision metric for estimating Phase 1 Maximum Tolerated Dose
Lin Yuan
Favorite
Yuan, Xuanzhen

College of Pharmacy, University of Iowa
(M-133) Utilizing Opportunistic Clinical Study and Population-Based Pharmacometric Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill Patients
Xuanzhen Yuan
Favorite
Yu, Ruihong

Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, NY, 14214, USA
(M-130) Across-species meta-analysis of methylprednisolone reversible metabolism and pharmacokinetics utilizing allometric and scaling model approaches
Ruihong Yu
Favorite
(M-131) Physiologically based pharmacokinetic modeling the reversible metabolism and tissue-specific partitioning of methylprednisolone and methylprednisone in rats
Ruihong Yu
Favorite
Z
Zahir, Hamim
(T-136) Unique Effect of the High-Fat Meal on the Pharmacokinetics of Omaveloxolone Explained by Physiologically Based Biopharmaceutics Modeling
Hamim Zahir
Favorite
Zhang, Lily

Fred Hutch cancer center
(W-140) Pharmacokinetics Analysis of Serum and Rectal Tissue Concentrations of VRC01 and VRC01LS in People Without HIV in a Phase 1 Clinical Trial (HVTN 116)
Lily Zhang
Favorite
Zhang, Sihong

University of North Carolina at Chapel Hill
(T-138) Modeling Patient Risk Factors and their Role in Dose Optimization for Oncological Trials
Sihong Zhang
Favorite
Zhang, Xianwei

Alnylam Pharmaceuticals
(M-134) A Minimal Physiology-based Pharmacokinetics Model of Blood-Brain Barrier Transport for Monoclonal Antibodies Targeting the Transferrin Receptor
Xianwei Zhang
Favorite
Zhang, Xinwen

Clinical Pharmacology Modeling & Simulation, Amgen
(T-137) Mechanistic physiologically-based pharmacokinetic platform model to characterize risk of cytochrome P450 based drug-drug interactions for bispecific T cell engagers in oncology patients
Xinwen Zhang
Favorite
Zhang, Yi

Critical Path Institute
(M-135) A Bayesian disease progression model for Major Depressive Disorder
Yi Zhang
Favorite
(M-136) A time-to-event model for Bronchopulmonary dysplasia based on real-world data
Yi Zhang
Favorite
Zhao, Janet

Certara Inc.
(M-137) A Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Model for Covalent Bruton Tyrosine Kinase Inhibitor TL-895
Janet Zhao
Favorite
Zhao, Molly
(W-083) Model-based Meta-Analysis (MBMA) to Inform Immuotherapy (IO) Treatment Decisions in Metastatic Non-Small Cell Lung Cancer (mNSCLC)
Molly Zhao
Favorite
Zhao, Yuan

EMD Serono, Billerica, MA, USA
(W-141) Disease progression modeling of myositis from real-world data
Yuan Zhao
Favorite
Zheng, Fudan

Johnson & Johnson Innovative Medicine
(T-139) Population Pharmacokinetics and Exposure-response Analyses of Amivantamab Administered in Combination with Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Non-Small Cell Lung Cancer
Fudan Zheng
Favorite
Zheng, Xirong

Bristol Myers Squibb
(M-138) Population cellular kinetics of idecabtagene vicleucel in patients with triple-class-exposed relapsed/refractory multiple myeloma
Xirong Zheng
Favorite
(M-139) Longitudinal modeling of a mechanism-based biomarker informs selection of golcadomide doses and dosing schedules for optimization in patients with relapsed or refractory non-Hodgkin lymphoma
Xirong Zheng
Favorite
Zhong, Rui

University of North Carolina at Chapel Hill
(T-140) Modeling the frequency of toxicity-induced dose modifications and their impact on conventional exposure-response analysis in targeted therapy
Rui Zhong
Favorite
Zhou, Jessie

Johnson and Johnson
(M-140) Nipocalimab pharmacokinetic/pharmacodynamic and exposure-response modeling in pregnancies at risk for early-onset severe (EOS) HDFN
Jessie Zhou
Favorite
Zhou, Jia

Janssen Research & Development, LLC, Spring House, PA, USA
(T-141) Model-Based Exploration of the Impact of Prophylactic Tocilizumab on IL-6 Dynamics in Multiple Myeloma Patients Receiving Teclistamab Treatment
Jia Zhou
Favorite
Zhou, Jiawei

Pfizer, Inc.
(M-141) Population joint modeling of SARS-CoV-2 neutralizing titer dynamics after COVID-19 mRNA vaccine booster administration
Jiawei Zhou
Favorite
Zhu, Rui

Genentech
(M-142) Evaluating concomitant medication use in cystic fibrosis patients using real-world data (RWD) to inform drug-drug interaction risk assessment and clinical trial design of GDC-6988
Rui Zhu
Favorite